Compare Ascendis Pharma A/S (ASND) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Palo Alto Networks Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Palo Alto Networks Inc trades at $327.96 (market cap $265.62B). The key difference: Palo Alto Networks Inc is far larger — about 15× Ascendis Pharma A/S's market cap. Which is the better fit depends on your goals.
| ASND | PANW | |
|---|---|---|
Market Cap | $17.74B | $265.62B |
Sector | Health | Technology |
52-Week High | $277.18 | $357.53 |
52-Week Low | $163.32 | $141.67 |
Enterprise Value | $18.11B | $264.58B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Palo Alto Networks (PANW) trades at $325.91, down 3.67% today, but maintains strong analyst support with 74% buy ratings and a $334.71 consensus target. The stock shows bullish technical signals with support at $321 and resistance at $347. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $0.85 surpassing the $0.793 estimate. Revenue growth remains robust, climbing from $5.5B in 2022 to $9.22B in 2025, though valuation multiples appear elevated with a P/E of 283.4.
PANW's outlook is supported by AI-driven cybersecurity demand and platformization strategy, but high valuation and competitive pressures present risks. The company's positive cash flow trends and analyst optimism suggest potential upside, though investors should weigh premium pricing against growth sustainability in a dynamic security market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
